Cargando…

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs), transdermal fentanyl patches, and transmucosal buprenorphine are probably the most commonly used options for providing post-operative analgesia in the early at-home period. However, these require daily administration or are associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enomoto, Masataka, Kigin, Patricia D., Bledsoe, David, Slone, Robyn, Hash, Jonathan, Smith, Charles E., Lascelles, B. Duncan X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259973/ https://www.ncbi.nlm.nih.gov/pubmed/28118835 http://dx.doi.org/10.1186/s12917-017-0943-5

Ejemplares similares

Late-onset osteosarcoma after onychectomy in a cat
por: Breitreiter, Katrina
Publicado: (2019)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Initial exploration of the discriminatory ability of the PetPace collar to detect differences in activity and physiological variables between healthy and osteoarthritic dogs
por: Rowlison de Ortiz, Avery, et al.
Publicado: (2022)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

An extended release local anaesthetic: potential for future use in veterinary surgical patients?
por: Lascelles, B. Duncan X., et al.
Publicado: (2016)

The Effects of Onychectomy (Declawing) on Antebrachial Myology across the Full Body Size Range of Exotic Species of Felidae
por: Martens, Lara L., et al.
Publicado: (2023)

A Pilot, Open-Label Study to Evaluate the Efficacy of Intra-Articular Administration of a Caninized TNF Receptor Fc Fusion Protein as a Treatment for Osteoarthritis-Associated Joint Pain
por: Nakanishi, Aoi, et al.
Publicado: (2022)

Defining the local nerve blocks for feline distal thoracic limb surgery: a cadaveric study
por: Enomoto, Masataka, et al.
Publicado: (2016)

Development of a checklist for the detection of degenerative joint disease-associated pain in cats
por: Enomoto, Masataka, et al.
Publicado: (2020)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings
por: Boyett, Brent, et al.
Publicado: (2023)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

The effect of spontaneous osteoarthritis on conditioned pain modulation in the canine model
por: Chiu, King Wa, et al.
Publicado: (2020)

Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats
por: Zhang, Mingyun, et al.
Publicado: (2022)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post‐operative hypersensitivity in an incisional pain model in mice (Mus musculus)
por: Navarro, Kaela, et al.
Publicado: (2021)

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats
por: Enomoto, Masataka, et al.
Publicado: (2019)

Correlation of Artemin and GFRα3 With Osteoarthritis Pain: Early Evidence From Naturally Occurring Osteoarthritis-Associated Chronic Pain in Dogs
por: Minnema, Laura, et al.
Publicado: (2020)

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route
por: Kharidia, Jahnavi, et al.
Publicado: (2021)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Evaluation and comparison of pharmacokinetic profiles and safety of two extended-release buprenorphine formulations in common marmosets (Callithrix jacchus)
por: Fabian, Niora J., et al.
Publicado: (2023)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats
por: Cowan, Alan, et al.
Publicado: (2015)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone
por: Marsden, John, et al.
Publicado: (2022)

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation
por: Lowry, Natalie, et al.
Publicado: (2022)

Functional outcome measures in a surgical model of hip osteoarthritis in dogs
por: Little, Dianne, et al.
Publicado: (2016)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis
por: Langworthy, Michael J., et al.
Publicado: (2019)

Buprenorphine
por: Mazurek, Jaroslaw, et al.
Publicado: (2014)

Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study
por: Gruen, Margaret E., et al.
Publicado: (2021)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Histological and molecular characterisation of feline humeral condylar osteoarthritis
por: Ryan, John M, et al.
Publicado: (2013)

Serum artemin is not correlated with sensitivity within dogs with naturally occurring osteoarthritis pain
por: Gupta, Ankita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1c38pi5hhk8t5tskv9l9117q2n